An observational study in Chronic Myeloproliferative Disorders, sponsored by Sohag University. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-15.
Sponsored by Sohag University · Observational
Pulmonary hypertension (PH) is a complex condition that may be related to many clinical conditions. It is a serious disorder with a high morbidity and mortality rates. PH is classified into five groups according to clinical characteristics, pathological findings, hemodynamic characteristics and treatment response (Galie N, et al., 2016). These five groups include pulmonary arterial hypertension, PH due to left sided heart disease, PH due to lung disease and/or hypoxia, chronic thromboembolic pulmonary hypertension, or other pulmonary arterial obstruction and PH with unclear and/or multifactorial mechanisms (Simonneau G, et al., 2013).
PH is a major complication of several hematologic disorders including myeloproliferative neoplasms (MPNs). MPNs are a group of diseases characterized by uncontrolled proliferation of at least one myeloid series due to an abnormal hematopoietic cell clone. There are different types of MPNs including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) \& chronic myeloid leukemia ( CML). Myeloproliferative neoplasms (MPNs) are included in group 5 PH (Arber DA, et al., 2016).
This study will analyze the clinical and laboratory data of MPNs patients and correlate them with development of PH in these patients aiming to identify parameters that can predict PH in MPNs patients and thus, identifying MPNs patients at highest risk for PH who require close monitoring \& screening for PH hoping that early detection and management of PH in MPNs patients can improve morbidity, prognosis and survival in those patients
640 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.
This study's planned enrollment of 150 is close to the median of 143 across 113 observational studies indexed under Myeloproliferative Disorders.
Browse Myeloproliferative Disorders studies →Sohag University is the lead sponsor of 1,218 studies on the registry; 627 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The outpatient Hematology Clinic at Sohag University Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnostic Test: Echocardiography
Diagnostic Test: Echocardiography
Trans-thoracic Echocardiography
Prevalence of pulmonary hypertension in chronic myeloproliferative disorders patients
Prevalence of pulmonary hypertension in chronic myeloproliferative disorders patients
Time frame: 2 years
Identification of independent different predictors of pulmonary hypertension in chronic myeloproliferative disorders patients
Identification of independent different predictors of pulmonary hypertension in chronic myeloproliferative disorders patients
Time frame: 2 years
No study locations are listed for this record.
Plan to share: Undecided
This study is status unknown, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Myeloproliferative Disorders →